Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. - Wikidata - wikimedia - TriplyDB

Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.

Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.

http://www.wikidata.org/entity/Q35789894

about

Predictive biomarkers for treatment selection: statistical considerations Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells 3D Slicer as an image computing platform for the Quantitative Imaging Network Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy.DFNA5 promoter methylation a marker for breast tumorigenesis Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine.Biomarkers of HIV-associated Cancer.Effective incorporation of biomarkers into phase II trials Angiogenesis inhibitors: current strategies and future prospects.Clinical utility of quantitative imaging.ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma.Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract.A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium.Drug development in oncology: classical cytotoxics and molecularly targeted agents.Biomarker development in the context of urologic cancers A Comparative Analysis of Drug-Induced Hepatotoxicity in Clinically Relevant Situations.Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.Oncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patient Molecular imaging as a tool for personalized and targeted anticancer therapy.Functional PET imaging in cancer drug development.Mechanistic biomarkers for clinical decision making in rheumatic diseases.Clinical applications of metabolomics in oncology: a review.Validation of analytic methods for biomarkers used in drug development Industry perspectives on biomarker qualification.A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer.Use of nuclear magnetic resonance-based metabolomics in detecting drug resistance in cancer Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer.A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment.DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine.Early oncology clinical trial design in the era of molecular-targeted agents.Novel methodologies in metabolic profiling with a focus on molecular diagnostic applications.Assessing the in vivo efficacy of biologic antiangiogenic therapies.Surrogate end points for long-term outcomes in chronic myeloid leukemia.The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer.Biomarkers in Barrett's oesophagus and oesophageal adenocarcinoma.Optimizing investigator-led oncology research in Europe.Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy.A novel method for assessing in vitro oncology drug combinations using growth rates.High-throughput metabolic profiling based on small amount of hepatic cells.Method development of glycoprotein biomarkers for cancers.

P2860

Q26778367-ACED737E-2383-46CE-9762-AFB98B10D76C Q28477427-DAE38362-3FD9-48A9-BBFB-0A075594F5EB Q28727260-F97BFF1C-9C27-41E6-A721-4C8B05EDE27C Q30238470-64DBCF18-5F6C-44E1-8871-6D8C4ADF60C8 Q33761973-8AD0118F-73A5-47CA-9909-FE818D14EB20 Q33827699-43788A94-3B0A-4802-978B-43BD467A2E92 Q33856851-C6857BA8-0411-4010-ACE6-7CEB0F181187 Q33870594-73221DE8-430E-41EB-9578-2D6D4D451F0D Q34056376-C1DA6147-F132-4112-B397-89D83AC68363 Q34656915-D663CBF1-0CAF-4F39-B091-30734C7B8016 Q34712780-3D1C7968-2EFE-4444-8F9B-B977730117B4 Q35136824-F26AD031-EC23-4BD5-9285-68C03DC6A216 Q35584239-B7A7239F-259A-4444-A7E2-4AB3B84644B6 Q35827606-3C1FE885-3443-424E-9572-95371C06ABE1 Q35906352-388CD596-83DC-4610-9E54-7133536F0237 Q36267296-A443F363-40D3-4925-979B-8388B3F9282B Q36392598-EF8E3D51-35BD-43CC-A99F-D1E22E984E81 Q36732058-2932FEAE-622B-46D6-AAA5-F85F232F4342 Q36752665-7FAD2852-4941-4D39-AC16-941DD8096950 Q36768305-73C31606-CEBF-4DA9-AAC6-EED43C2C9185 Q36905584-2ABD5F56-5482-4E1F-B29C-739B05D41FEF Q37177549-D666316F-8A32-4DE0-AD6E-341660B48270 Q37284255-DA6D4293-0A68-40F9-9649-04AE5CB76B0B Q37341324-6041335B-C113-41B3-A381-B10445067C8E Q37357251-6C8925B1-C54D-4859-8507-E43FC78131FF Q37374479-4E8505CD-FC17-44C5-9E97-F61014E1E5F5 Q37377316-E54F7306-507E-4D5F-8EE9-365DF9804DE1 Q37411548-5AD626FE-1FA9-4538-969A-6875BFEE064B Q37736567-C436C456-6648-4102-9B2D-8AC35B51D43D Q37783623-5A070469-AB2A-4ACB-84C9-5E71C4902A2E Q38019000-9B15C517-2988-4270-BDB7-456619283FC0 Q38051013-68F0C296-F720-4B68-B373-8D74A09A70FA Q38079249-DEC26A3E-E99E-49D2-B2C6-99F6E25E8559 Q38083816-E1D93D72-60E6-4210-A6B0-4F19B038BCCC Q38089259-C9A62BE8-6BEA-4E11-8C20-4CF39F56AF0F Q43188728-40FB769E-5F28-43DA-95C9-F0426445FB2C Q43679493-1771E91A-F8E9-49B5-8560-3784E95EEC05 Q48022727-3287BD18-4F01-467F-BC7C-C43B0DE3E731 Q48149123-71CFD598-A7A2-4124-9804-D7DA77791B46 Q53106084-1EC769CD-CAB5-416D-9E12-B994BA8133E6

P2860

Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.

http://www.wikidata.org/entity/Q35789894

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Rationale for biomarkers and s ...... ven oncology drug development.

@ast

Rationale for biomarkers and s ...... ven oncology drug development.

@en

type

label

Rationale for biomarkers and s ...... ven oncology drug development.

@ast

Rationale for biomarkers and s ...... ven oncology drug development.

@en

prefLabel

Rationale for biomarkers and s ...... ven oncology drug development.

@ast

Rationale for biomarkers and s ...... ven oncology drug development.

@en

P1433

Q35789894-81EB1AD9-E97F-4D25-98C6-F0E5EA8B778E

P1476

Q35789894-667C93FF-9613-46B5-8DA0-668F757C2711

P2093

Q35789894-02BD7800-5A1D-4BEA-87D3-C6F2F205C256

Q35789894-4CA7D7A8-C05C-4C9B-B798-1D2208D0EE23

Q35789894-5AA3F9D2-36CD-4A15-ABC6-7D54A2FB7175

Q35789894-5E9AE5DB-FDC8-4A45-860D-8497B1CEC955

Q35789894-6E35D42B-303B-4767-8A7D-7B71433BAAF0

Q35789894-74F51182-BC4F-4B42-82C4-02B3AABE2A44

Q35789894-BEE8E42C-232A-48F0-9942-6F2B9BBBCFAE

Q35789894-C450DF10-0983-41A2-827B-2A1827949637

Q35789894-CF0A3D00-28CD-4FCD-B594-3423F2CD7BA9

Q35789894-D18F1DAF-FC1B-43E0-86F8-19BF13708764

P304

Q35789894-FF581E1D-F7C7-4B99-AF28-8641C3EADDC4

P31

Q35789894-5614096C-D30A-412B-A41B-DEED9C8CF6EF

P356

Q35789894-DEDC2B72-27D7-4516-9C87-0E42E6662FA7

P407

Q35789894-1C63BE45-95D1-4AD6-B250-40176EE62753

P433

Q35789894-51EF1DA4-5B4A-4C8D-9658-034EDFA1FBB1

P478

Q35789894-C40EDCB2-8721-4589-8065-24A920B17F17

P577

Q35789894-25B99DD8-416A-4726-86D7-891ADF3A51DF

P698

Q35789894-75D835FD-B57E-40B2-9C0E-02FDEB5FB874

P921

Q35789894-3AD8D81F-7965-4CB6-A2F3-F6DD00BFCD81

P356

1078-0432.CCR-03-0785

P1433

Clinical Cancer Research

P1476

Rationale for biomarkers and s ...... ven oncology drug development.

@en

P2093

Bruce A Chabner

http://www.w3.org/2001/XMLSchema#string

Caroline C Sigman

http://www.w3.org/2001/XMLSchema#string

David R Parkinson

http://www.w3.org/2001/XMLSchema#string

Dennis J Slamon

http://www.w3.org/2001/XMLSchema#string

Gary J Kelloff

http://www.w3.org/2001/XMLSchema#string

J Carl Barrett

http://www.w3.org/2001/XMLSchema#string

John W Park

http://www.w3.org/2001/XMLSchema#string

Jonathan Peck

http://www.w3.org/2001/XMLSchema#string

Raymond W Ruddon

http://www.w3.org/2001/XMLSchema#string

Robert S Kerbel

http://www.w3.org/2001/XMLSchema#string

P304

3885-3896

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-03-0785

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2004-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15173098

http://www.w3.org/2001/XMLSchema#string

P921